Omega-3 polyunsaturated fatty acids in the treatment of atherogenic dyslipidemia

Angela Pirillo, Alberico L. Catapano

Research output: Contribution to journalArticlepeer-review


Epidemiological studies have established an association between high triglycerides (TG) plasma levels and increased cardiovascular risk. Increased TG levels, commonly coupled with low HDL-C levels, are common in high cardiovascular risk subjects including those with dyslipidemia, metabolic syndrome and type 2 diabetes. Management of hypertriglyceridemia (HTG) includes lifestyle modification for mild-to-moderate HTG and pharmacological therapies for the treatment of high and very high TG levels. Among drugs, fibrates, nicotinic acid and omega-3 polyunsaturated fatty acids may be considered. Omega-3 fatty acids reduce plasma TG levels by several mechanisms; beside the effects on TG, omega-3 can also influence the levels of other lipids and lipoproteins including HDL-C and LDL-C. Clinical trials have also shown that omega-3 fatty acid supplementation is effective also when added in combination with other lipid-lowering drugs. These findings suggest that omega-3 fatty acids may be usefully considered for the management of high TG levels.

Original languageEnglish
Pages (from-to)237-242
Number of pages6
JournalAtherosclerosis Supplements
Issue number2
Publication statusPublished - 2013


  • Dyslipidemia
  • Hypertriglyceridemia
  • Omega-3 polyunsaturated fatty acids
  • Triglycerides

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Internal Medicine
  • Medicine(all)


Dive into the research topics of 'Omega-3 polyunsaturated fatty acids in the treatment of atherogenic dyslipidemia'. Together they form a unique fingerprint.

Cite this